Fundraising FoxAxelia Oncology
Melbourne, AU · 2 known investors
Find your way into Axelia Oncology
Sign up to see every warm intro you have to Axelia Oncology
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Axelia Oncology team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Axelia Oncology is a biopharmaceutical company developing AXA-042, a selective immunological agent designed to activate innate immune responses against checkpoint-insensitive solid tumors. The company focuses on oncology therapeutics through activation of TLR2/6 pathways.
Founders & leadership
DJ
David JacksonFounder (Laboratory research origin)
GM
Grant MchlachlanChief Executive Officer
Investors · 2
In the news
Frequently asked questions
- What does Axelia Oncology do?
- Axelia Oncology is a biopharmaceutical company developing AXA-042, a selective immunological agent designed to activate innate immune responses against checkpoint-insensitive solid tumors. The company focuses on oncology therapeutics through activation of TLR2/6 pathways.
- Who founded Axelia Oncology?
- Axelia Oncology was founded by David Jackson.
- Who are Axelia Oncology's investors?
- Axelia Oncology's investors include Stoic VC, UniSeed Pty Ltd..
- Where is Axelia Oncology headquartered?
- Axelia Oncology is headquartered in Melbourne, AU.